⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

Official Title: A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

Study ID: NCT04740021

Study Description

Brief Summary: LP002 is a highly selected recombinant humanized anti-PD-L1 monoclonal antibody. This is a single-arm, multicenter study to evaluate the efficacy and safety of LP002 in combination with chemotherapy in patients with extensive stage samll cell lung cancer.

Detailed Description:

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Henan Cancer Hospital, Zhengzhou, Henan, China

Hunan Cancer Hospital, Changsha, Hunan, China

Affiliated Hospital Of Jiangnan University, Wuxi, Jiangsu, China

The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China

Shandong Cancer Hospital, Jinan, Shandong, China

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Xinjiang Medical University Cancer Center, Urumqi, Xinjiang, China

Yunnan Cancer Hospital, Kunming, Yunnan, China

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: